Date Name Title Filing Type Shares Traded Price Total Held
May 07, 2005
Director
Director Form 4 Other acquisition or disposition (describe transaction) 156,097 -- 43,903
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 158,079 $52.03 908,303
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 158,079 -- --
Dec 16, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 158,079 -- 158,079
Aug 06, 2021
Director, President & CEO
Director, President & CEO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 160,000 $52.03 596,176
Aug 06, 2021
Director, President & CEO
Director, President & CEO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 160,000 -- --
Dec 16, 2011
Director, President & CEO
Director, President & CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 160,000 -- 160,000
Feb 15, 2024
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 172,723 $399.66 925,209
Feb 15, 2024
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 172,723 -- --
Dec 16, 2015
Director, President & CEO
Director, President & CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 172,723 -- 172,723

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.